Cancer app takes top prize in Janssen digital awards
pharmafile | November 22, 2013 | News story | Medical Communications, Sales and Marketing | Cancer, J&J, JJ, app, digital, px healthcare
A start-up firm established by medical scientists that develops mobile apps for cancer patients has taken first place in the inaugural Digital Health Masterclass Challenge, hosted by Janssen Healthcare Innovation.
The winning technology is designed to personalise medical support for patients with cancer and improve the patient-doctor relationship.
Janssen Healthcare Innovation says that this application highlights “how digital health businesses across Europe are fast securing their position as key players in today’s health ecosystem”.
Pitching to a select panel of judges against 19 fellow digital health start-ups at the Masterclass Challenge, Px Healthcare – an Amsterdam-based firm – secured first place and the top prize of €30,000 to help grow its business.
Taking second place and a prize of €15,000 was DrEd, a new breed of online doctor that provides remote medical consultations for a range of conditions including sexual health testing and travel health.
Currently operating out of the UK, Germany, Austria and Switzerland, the online doctor platform offers video consultations and can also issue electronic prescriptions.
Onco Drug Personalised Med (ODPM), a French-based start-up that develops digital solutions for personalised treatment for cancer patients, secured third place and a prize of €5,000.
ODPM has developed web-based calculators to determine the risk of toxicity in patients to be treated with fluoropyrimidines, and provides dose adaptation to improve quality of life during chemotherapy and reduce hospital costs.
Marco Mohwinckel, partner at Janssen Healthcare Innovation said: “We want to congratulate not just the winners of this award, but all 20 companies who were selected to take part in the Digital Health Masterclass Challenge. The judging panel was hugely impressed by the digital healthcare solutions demonstrated by all the participating companies. Reaching a final decision was not easy.”
Twenty digital health start-ups from nine European countries were selected to participate in the Masterclass from over 100 applicants. Each of the start-ups has developed an innovative product, service or proposition using the latest technologies such as mobile apps, cloud-based solutions and wireless sensing technologies to addresses a particular healthcare need.
Mohwinckel continued: “I’m proud to say we’ve left a mark and it’s been rewarding to see friendships form and ideas grow. I’m sure many of these digital health start-ups will now be accelerating their ideas as a result of the Masterclass.”
Patrick Verheyen, head of Johnson & Johnson Innovation in London, added: “Connecting innovators with the right resources has the potential to accelerate new health solutions and improve the lives of patients. By pooling the expertise across the Johnson & Johnson Family of Companies, we can be a catalyst to these rising stars of digital health and others in the innovation ecosystem.
Ben Adams
Related Content
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, …
T-cell therapy – the evolution of cancer treatments
The current forms of immunotherapy, how T cell therapy works and what the future holds
